In This Article:
Let’s dig into the relative performance of Samsara (NYSE:IOT) and its peers as we unravel the now-completed Q4 data analytics earnings season.
Organizations generate a lot of data that is stored in silos, often in incompatible formats, making it slow and costly to extract actionable insights, which in turn drives demand for modern cloud-based data analysis platforms that can efficiently analyze the siloed data.
The 5 data analytics stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 2.5% while next quarter’s revenue guidance was in line.
While some data analytics stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.9% since the latest earnings results.
Samsara (NYSE:IOT)
One of the few public companies where Marc Andreessen is a Board member, Samsara (NYSE:IOT) provides software and hardware to track industrial equipment, assets, and fleets.
Samsara reported revenues of $346.3 million, up 25.3% year on year. This print exceeded analysts’ expectations by 2.9%. Overall, it was a strong quarter for the company with EPS guidance for next quarter exceeding analysts’ expectations and an impressive beat of analysts’ EBITDA estimates.
The stock is down 13% since reporting and currently trades at $36.44.
We think Samsara is a good business, but is it a buy today? Read our full report here, it’s free.
Best Q4: Palantir (NASDAQ:PLTR)
Started by Peter Thiel after seeing US defence agencies struggle in the aftermath of the 2001 terrorist attacks, Palantir (NYSE:PLTR) offers software as a service platform that helps government agencies and large enterprises use data to make better decisions.
Palantir reported revenues of $827.5 million, up 36% year on year, outperforming analysts’ expectations by 6.8%. The business had an exceptional quarter with a solid beat of analysts’ billings estimates and an impressive beat of analysts’ EBITDA estimates.
Palantir scored the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 3.5% since reporting. It currently trades at $80.94.
Is now the time to buy Palantir? Access our full analysis of the earnings results here, it’s free.
Weakest Q4: Health Catalyst (NASDAQ:HCAT)
Founded by healthcare professionals Tom Burton and Steve Barlow in 2008, Health Catalyst (NASDAQ:HCAT) provides data and analytics technology to healthcare organizations, enabling them to improve care and lower costs.